ProfileGDS5678 / 1417717_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 6% 6% 6% 6% 6% 6% 7% 6% 9% 6% 6% 5% 6% 6% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.128566
GSM967853U87-EV human glioblastoma xenograft - Control 22.108766
GSM967854U87-EV human glioblastoma xenograft - Control 32.116116
GSM967855U87-EV human glioblastoma xenograft - Control 42.071266
GSM967856U87-EV human glioblastoma xenograft - Control 52.067246
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.170566
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.185457
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.099726
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.196919
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.114196
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.100826
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.069365
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.115926
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.1156